MaxCyte (MXCT) vs OmniAb (OABI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
OmniAb (OABI) has outperformed MaxCyte (MXCT) over the past year, gaining 163.3% versus a loss of 18.0%. Over five years, OABI leads with a -53.4% price change compared with -85.9% for MXCT. OmniAb is the larger company by market cap ($679.7 million vs $141.5 million), about 4.8 times the size, while MaxCyte is growing revenue faster (-14.5% vs -29.3%).
MaxCyte converts more of its revenue into profit, with a net margin of -135.1% versus -347.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MXCT | OABI |
|---|---|---|
| Share price | $1.37 | $4.66 |
| Market cap | $141.45M | $679.71M |
| 1-day change | +7.03% | -7.36% |
| YTD return | -11.61% | +151.89% |
| 1-year return | -17.96% | +163.28% |
| 5-year return | -85.92% | -53.40% |
| EPS (TTM) | $-0.26 | $-0.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $33.03M | $18.67M |
| Revenue growth (YoY) | -14.50% | -29.27% |
| Net income (latest FY) | $-44.63M | $-64.78M |
| Gross margin | 81.16% | — |
| Operating margin | -157.14% | -369.49% |
| Net margin | -135.14% | -347.04% |
| 52-week high | $1.80 | $5.45 |
| 52-week low | $0.643 | $1.35 |
| Distance from 52-week high | -23.89% | -14.50% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +200.00% | +78.76% |
| Average volume | 1.04M | 1.46M |
| Shares outstanding | 103.25M | 145.86M |
| Employees | 91 | 89 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OmniAb is about 4.8 times larger than MaxCyte by market value ($679.71M vs $141.45M).
- OABI has outperformed MXCT by 181.2 percentage points over the past year.
- MaxCyte is more profitable, keeping -135.1 cents of every revenue dollar as net income versus -347.0 cents for OmniAb.
- MaxCyte grew revenue faster in its latest fiscal year (-14.50% vs -29.27%).
About MaxCyte
MXCT stock →MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 91 employees
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 89 employees
MXCT vs OABI FAQ
Which is bigger, MaxCyte or OmniAb?
OmniAb (OABI) is larger, with a market capitalization of $679.71M compared with $141.45M for MaxCyte (MXCT).
Which stock has performed better over the past year, MXCT or OABI?
OABI returned +163.28% over the past 12 months, compared with -17.96% for MXCT (price return, excluding dividends). Past performance does not predict future results.
Are MaxCyte and OmniAb in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.